Kumar Neil's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Dec 21, 2022
- Accession no.
- 0001209191-22-062377
- Filed
- Dec 21, 2022
- Trade date
- Dec 21, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kumar NeilCIK 0001742485 | Director, Officer (CEO and President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 21, 2022 | Common Stock | SSaleDisposed | −200,000 | –F1 | – | 995,686 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reporting person contributed shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund. The Issuer's common stock was valued at $8.26 per share for the purposes of determining the number of shares of the exchange fund issuable to the reporting person.
Referenced by the price of 1 transaction in Table I.